Bellevue : Group concludes acquisition of Adamant Biomedical Investments AG from Zürcher Kantonalbank

Bellevue Group consummated the acquisition of Adamant Biomedical Investments AG from Zürcher Kantonalbank as scheduled effective September 30, 2014. Bellevue Group is acquiring Adamant's entire range of investment funds and its mandate business in the healthcare sector. Total acquired assets under management amount to CHF 831 million, raising Bellevue Asset Management's AuM to CHF 3.9 billion. Bellevue Asset Management and Adamant will officially merge on January 1, 2015 to optimize the exploitation of all product and market synergies.

"The acquisition of Adamant marks another milestone in the corporate development of Bellevue Asset Management and will contribute to our sustainable income growth. We are looking forward to working with the Adamant team to strengthen and expand our leading position as a provider of investment solutions in the healthcare sector," remarks André Rüegg, CEO of Bellevue Asset Management.

Dr. Cyrill Zimmermann, CEO of Adamant: "Bellevue Asset Management's business model allows us to continue our long-standing collaboration with Zürcher Kantonalbank and at the same time pursue interesting business opportunities both in our domestic market and internationally."   

  
Contacts:

Media Relations:

André Rüegg, CEO Bellevue Asset Management

Telephone +41 44 267 67 00, Fax +41 44 267 67 01, aru@bellevue.ch

Dr. Cyrill Zimmermann, CEO Adamant Biomedical Investments AG

Telephone +41 61 275 92 11, Fax +41 61 275 92 01, cyrill.zimmermann@adamantinvest.com

Zürcher Kantonalbank, Media Relations

Telephone +41 44 292 29 79, Fax +41 44 292 38 23, medien@zkb.ch

Investor Relations:

Daniel Koller, CFO Bellevue Group

Telephone +41 44 267 67 00, Fax +41 44 267 67 01, ir@bellevue.ch

Bellevue Group

Bellevue Group is an independent Swiss financial boutique listed on the SIX Swiss Exchange. Established in 1993, the company and its approximately 80 employees are specialists in the fields of Brokerage, Corporate Finance and Asset Management. Bellevue Group includes the two subsidiaries Bank am Bellevue and Bellevue Asset Management. The bank boasts superb knowledge of the Swiss stock and bond market and offers independent research opinions and recommendations as well as viable solutions for capital market transactions. Bellevue Asset Management is focused on selected active equity investment strategies in growing markets, in healthcare industries as well as in other special themes such as entrepreneur-led companies.

Adamant Biomedical Investments AG

Adamant Biomedical Investments AG is an asset manager exclusively focused on healthcare. Its dedicated specialists have many years of experience in the fields of healthcare, investment research and portfolio management. Adamant's investment universe is the entire healthcare industry: Pharma, biotech, medtech, and generics as well as healthcare services and providers. Adamant was established in 2000 and is regulated by the Swiss Financial Market Supervisory Authority FINMA.

Zürcher Kantonalbank

Zürcher Kantonalbank is the market-leading full-service bank in the Zurich region and has a national as well as an international focus. With total assets of CHF 149.7 bn, Zürcher Kantonalbank is the largest of the cantonal banks and Switzerland's fourth-largest bank overall. Building on its extensive competence in the mortgage and credit businesses, it is also very successfully positioned in the investment and retirement-savings sector and with assets under management totaling CHF 191.9 bn today ranks among Switzerland's largest asset managers. As an independent institution incorporated under public law in the canton of Zurich, it benefits from a government guarantee. The canton provides a guarantee for all liabilities of Zürcher Kantonalbank should the latter's resources prove inadequate. Zürcher Kantonalbank is one of the few banks in the world to retain a first-class rating (AAA or Aaa) from rating agencies Standard & Poor's, Moody's, and Fitch.